Business Wire

Quectel, Giesecke+Devrient and Vodafone IoT collaborate to drive iSIM adoption in 2025

8.5.2025 10:00:00 CEST | Business Wire | Press Release

Share

Quectel Wireless Solutions, a global IoT solutions provider, is collaborating with companies across the integrated SIM (iSIM) value chain to simplify and accelerate iSIM adoption. Quectel, together with Giesecke + Devrient (G+D) and Vodafone IoT, have collaborated to streamline iSIM processes, create more tightly integrated market offerings and accelerate iSIM adoption in the manufacturing process.

iSIM offers significant operational cost and flexibility advantages to organisations and as a result, its adoption is significantly increasing. Analyst firm, Juniper Research, estimates that the number of iSIMs installed in connected devices globally will increase from 800,000 in 2024 to more than 10 million by 20261. This prediction covers the introductory phase of the technology, with the firm estimating that the number of iSIM connections will grow to 210 million by 2028 when take-up of the technology becomes more widespread.

The iSIM is set to transform IoT by offering a future-proof, tamper-resistant solution that is adaptable with new network technologies. Despite its advantages, some device manufacturers have faced challenges integrating iSIM due to having to contract with multiple network providers to ensure devices are compatible in individual countries and regions.

By combining the capabilities of Quectel, Vodafone IoT, and Giesecke+Devrient, the iSIM adoption process is significantly simplified – creating a unified, streamlined iSIM solution that automatically connects in over 180 countries worldwide using Vodafone’s extensive global IoT network. For large scale IoT deployments, this can result in significant cost savings as engineers are not needed to set up or manually configure devices.

“By working together to deliver iSIM we are breaking down the barriers to mass-scale adoption and helping to smooth the path to iSIM for customers across the globe,” commented Dominik Hierl, SVP Sales EMEA, Quectel Wireless Solutions. “We see iSIM as a transformative innovation that will reduce costs, accelerate time to market and limit friction and management burdens across IoT. iSIM enablement is a further foundational capability for Quectel as we help customers build a smarter world.”

“At G+D we recognize the important role iSIM will play and have already been at the forefront of other iSIM firsts in the world of connectivity and IoT. As such we’re always excited to partner with other like-minded experts to take solutions in this market to the next level,” said BeeGek Lim, Head of Business Line Digital Offerings at G+D.

Substantial savings can be made by organisations who use iSIMs because they lower the bill of materials (BOM) cost by removing the need for traditional SIM cards. In addition, by adding iSIM to chipsets or modules, the number of components required can be reduced, with fewer vendors involved – thereby reducing the overall complexity of production and size of the device.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

About Giesecke+Devrient

Giesecke+Devrient (G+D) is a global SecurityTech company headquartered in Munich, Germany. G+D makes the lives of billions of people more secure. The company shapes trust in the digital age, with built-in security technology in three segments: Digital Security, Financial Platforms and Currency Technology.

G+D was founded in 1852 and today has a workforce of more than 14,000 employees. In the fiscal year 2023, the company generated a turnover of 3 billion euros. G+D is represented by 123 subsidiaries and joint ventures in 40 countries. Further information: www.gi-de.com.

About Vodafone IoT

Vodafone IoT is a global leader in managed IoT connectivity services. With over 200 million devices connected across more than 180 countries, we provide businesses with reliable and secure IoT solutions, enabling them to effectively manage, monitor, and operate their IoT devices.

Our extensive network partnerships, spanning over 760 networks worldwide, allows us to deliver global IoT solutions that empower businesses to digitalise, transform and maximise the benefits of IoT.

By adopting IoT, businesses can benefit from smarter resource management, reducing emissions, and enhancing operational efficiency – helping them to operate more sustainably.

For more information, please visit Vodafone IOT, follow us on X at @VodafoneIoT or connect with us on LinkedIn at www.linkedin.com/company/vodafoneIoT.

_________________________

1https://www.juniperresearch.com/press/pressreleasesover-10m-global-isim-devices-forecast-within-two-years/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508880035/en/

Contacts

Media contact: media@quectel.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye